


First-Quarter Fiscal 2018 Earnings



January 29, 2018

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as “anticipates,” “believes,” “expects,” “estimates,” “is likely,” “predicts,” “projects,” “forecasts,” “objectives,” “may,” “will,” “should,” “plans” and “intends” and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the SEC, news releases and other written and oral communications. These forward-looking statements are based on Ashland’s expectations and assumptions, as of the date such statements are made, regarding Ashland’s future operating performance and financial condition, as well as the economy and other future events or circumstances. Ashland’s expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: the impact of acquisitions and/or divestitures Ashland has made or may make, including the acquisition of Pharmachem (including the possibility that Ashland may not realize the anticipated benefits from such transactions); Ashland’s substantial indebtedness (including the possibility that such indebtedness and related restrictive covenants may adversely affect Ashland’s future cash flows, results of operations, financial condition and its ability to repay debt); the potential that Ashland does not realize all of the expected benefits of the separation of its Valvoline business; the potential that the Tax Cuts and Jobs Act enacted on December 22, 2017 will have a negative impact on Ashland’s financial results, and severe weather, natural disasters, cyber events and legal proceedings and claims (including product recalls, environmental and asbestos matters). Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements, including, without limitation, risks and uncertainties affecting Ashland that are described in Ashland’s most recent Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland’s website at <http://investor.ashland.com> or on the SEC’s website at <http://www.sec.gov>. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this presentation whether as a result of new information, future events or otherwise. Information on Ashland’s website is not incorporated into or a part of this presentation.

Regulation G: Adjusted Results

The information presented herein regarding certain unaudited adjusted results does not conform to generally accepted accounting principles in the United States (U.S. GAAP) and should not be construed as an alternative to the reported results determined in accordance with U.S. GAAP. Ashland has included this non-GAAP information to assist in understanding the operating performance of the company and its reportable segments. The non-GAAP information provided may not be consistent with the methodologies used by other companies. All non-GAAP information related to previous Ashland filings with the SEC has been reconciled with reported U.S. GAAP results. Although Ashland provides forward-looking guidance for adjusted EBITDA, adjusted EPS and free cash flow, Ashland is not reaffirming or providing forward-looking guidance for U.S. GAAP-reported financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items without unreasonable effort.



First Quarter Summary



Ashland Global Holdings Inc.

Adjusted Results Summary¹

(\$ in millions) Preliminary	Fiscal First Quarter		
	Three months ended Dec. 31,		
	2017	2016	Change
Sales	\$ 842	\$ 704	20 %
Gross profit	\$ 230	\$ 189	22 %
Gross profit as a percent of sales	27.3 %	26.8 %	50 bp
Selling, general and admin./R&D costs	\$ 170	\$ 150	13 %
Operating income	\$ 64	\$ 42	52 %
Operating income as a percent of sales	7.6 %	6.0 %	160 bp
Depreciation and amortization	\$ 73	\$ 68	7 %
Earnings before interest, taxes, depreciation and amortization (EBITDA)	\$ 136	\$ 109	25 %
EBITDA as a percent of sales	16.2 %	15.5 %	70 bp
Net interest expense	\$ 31	\$ 30	3 %
Effective tax expense rate	18 %	18 %	- bp
Income from continuing operations	\$ 27	\$ 9	200 %
Diluted share count (million shares) ²	63	63	- %
Earnings per share (EPS)	\$ 0.42	\$ 0.14	200 %

Highlights

- Sales up 20% including 9 pts from acquisitions/divestitures and 3 pts from currency
- Reported net loss of \$4 million; loss from continuing operations of \$7 million or \$0.12 per diluted share
- EBITDA increased to \$136 million
- EPS equaled \$0.42 (includes ~\$0.04 negative impact from change in the tax rate)
- Excl. intangible amortization, adjusted EPS would have been \$0.71

Key Drivers

- All three reportable segments show organic year-over-year (YOY) improvements in sales and EBITDA
- SG&A growth driven largely by the impact of acquisition/divestiture and currency
- 18% effective tax rate driven primarily by new US corporate tax legislation

¹ Ashland's earnings release dated January 29, 2018, available on Ashland's website at <http://investor.ashland.com>, reconciles adjusted amounts to amounts reported under GAAP.

² Includes approximately 1 million of diluted shares for both periods that were excluded from the U.S. GAAP EPS calculation since there was a loss from continuing operations.

Specialty Ingredients Adjusted Results Summary¹

(\$ in millions) Preliminary	Fiscal First Quarter		
	Three months ended Dec. 31,		
	2017	2016	Change
Sales	\$ 550	\$ 482	14 %
Gross profit	\$ 174	\$ 154	13 %
Gross profit as a percent of sales	31.6 %	32.0 %	(40) bp
Selling, general and admin./R&D costs	\$ 130	\$ 114	14 %
Operating income	\$ 45	\$ 40	13 %
Operating income as a percent of sales	8.2 %	8.3 %	(10) bp
Depreciation and amortization	\$ 60	\$ 55	9 %
Earnings before interest, taxes, depreciation and amortization (EBITDA)	\$ 105	\$ 95	11 %
EBITDA as a percent of sales	19.1 %	19.7 %	(60) bp

Highlights

- Sales up 14% including 10 pts from acquisitions/divestitures and 2 pts from currency
- Gross profit up 13% including 8 pts from acquisitions/divestitures and 3 pts from currency

Key Drivers

YOY EBITDA Impact:

- \$9 million from volume/mix gains from focus on enhanced organic product mix across key end markets
- \$7 million decline in price vs. cost driven by higher than expected raw-material costs, primarily in industrial end markets, partially offset by new pricing programs
- \$1 million favorable SG&A (excluding the impact of acquisitions/divestitures and currency) due to cost discipline
- \$3 million benefit from favorable currency
- \$4 million positive net contribution from acquisitions/divestitures²; Pharmachem results remain on track for FY 2018

1 Ashland's earnings release dated January 29, 2018, available on Ashland's website at <http://investor.ashland.com>, reconciles adjusted amounts to amounts reported under GAAP.

5

2 Includes Pharmachem acquisition, construction China JV divestiture, and related corporate cost allocations.



Specialty Ingredients Sales Trends by End Market

(\$ in millions) Preliminary	Fiscal First Quarter		
	Three months ended Dec. 31,		
	2017	2016	Change
Personal care	\$ 139	\$ 133	5 %
Pharma	82	79	4 %
Adhesives	79	79	- %
Coatings	77	69	12 %
Construction, Energy, PS ¹	73	73	- %
Pharmachem	58	-	NM %
Nutrition & Other	42	39	8 %
Exited construction China JV	-	10	(100) %
Total sales	\$ 550	\$ 482	14 %

End Market Commentary

- Broad-based growth across end markets driven by targeted product mix enhancements
- Strong growth in Personal Care biofunctional ingredients
- New capacity enables robust volumes in key Pharma cellulosic excipients
- Adhesives sales flat but increased pricing
- Coatings growth led by key customer wins and favorable order patterns
- Seasonally slow quarter for Pharmachem
- Growth in Nutrition & Other driven by focused asset utilization initiatives
- Currency contributed 2 percentage points to sales growth²

1 Performance Specialties

2 Average USD / EUR of \$1.18 in current quarter compared to \$1.08 in prior-year period.

Composites

Adjusted Results Summary¹

(\$ in millions) Preliminary	Fiscal First Quarter Three months ended Dec. 31,		
	2017	2016	Change
Sales	\$ 218	\$ 165	32 %
Gross profit	\$ 40	\$ 35	14 %
Gross profit as a percent of sales	18.4 %	21.1 %	(270) bp
Selling, general and admin./R&D costs	\$ 26	\$ 22	18 %
Operating income	\$ 18	\$ 15	20 %
Operating income as a percent of sales	8.3 %	9.1 %	(80) bp
Depreciation and amortization	\$ 5	\$ 6	(17) %
Earnings before interest, taxes, depreciation and amortization (EBITDA)	\$ 23	\$ 21	10 %
EBITDA as a percent of sales	10.6 %	12.7 %	(210) bp

Highlights

- Sales up 32% including 10 ppts from acquisitions and 4 ppts from currency
- EBITDA up 10%

Key Drivers

- \$4 million of EBITDA growth from volume, mix and margin driven by strong growth in all key end markets, particularly in North America and Europe
- Continued pricing discipline through focus on commercial excellence and value selling
- \$4 million unfavorable SG&A due to reallocation of corporate costs

¹ Ashland's earnings release dated January 29, 2018, available on Ashland's website at <http://investor.ashland.com>, reconciles adjusted amounts to amounts reported under GAAP.

Intermediates & Solvents

Adjusted Results Summary¹

(\$ in millions) Preliminary	Fiscal First Quarter Three months ended Dec. 31,		
	2017	2016	Change
Sales	\$ 74	\$ 57	30 %
Gross profit	\$ 16	\$ -	NM %
Gross profit as a percent of sales	21.3 %	(0.9) %	2,220 bp
Selling, general and admin./R&D costs	\$ 8	\$ 7	14 %
Operating income (loss)	\$ 8	\$ (7)	NM %
Op. income (loss) as a percent of sales	11.1 %	(13.2) %	2,430 bp
Depreciation and amortization	\$ 8	\$ 7	14 %
Earnings before interest, taxes, depreciation and amortization (EBITDA)	\$ 16	\$ -	NM %
EBITDA as a percent of sales	21.6 %	- %	2,160 bp

Highlights

- Sales up 30%
- EBITDA increased to \$16 million
- EBITDA margin increased to 21.6%

Key Drivers

- \$16 million of EBITDA growth from volume, mix and margin driven by higher BDO prices YOY and customer wins in derivatives
- Market demand remains healthy across all regions
- Catalyst change at Lima, Ohio facility in prior-year period

¹ Ashland's earnings release dated January 29, 2018, available on Ashland's website at <http://investor.ashland.com>, reconciles adjusted amounts to amounts reported under GAAP.

Outlook Summary



Ashland Global Holdings Inc.

Impact of New Tax Law

Highlights

- Reset FY 2018 book effective tax rate (ETR) to a range of 16 – 20%
- FY 2018 Adjusted EPS outlook based on 18% rate
- Cash tax rate (CTR) expected to be in the current range of 20 – 25%
- Cash cost of ~\$160 million for mandatory repatriation; offset by lower deferred tax liabilities of ~\$126 million
- FY 2018 targeted cash repatriation of ~\$500 million, of which ~\$300 million used for debt reduction thus far in fiscal-second quarter 2018

Additional Information

- Lower US corporate tax rate effective for Ashland in FY 2018
- Other key provisions do not apply until FY 2019 (e.g., interest expense disallowance, 100% expensing of certain capital expenditures, and new international tax rules)
- Lower US corporate tax rate increases Ashland's ETR as a result of the reduction to the ETR benefit of our US book loss
- Transition to territorial tax system will "unlock" our foreign cash going forward
- We plan to provide an update on additional impacts to FY 2019 ETR and CTR later in the year

Ashland Global Holdings Inc.

Fiscal Year 2018 Outlook

Highlights

- Reaffirm all operating segment Adjusted EBITDA outlooks
- Reaffirm FY free cash flow outlook¹
- Update FY Adj. EPS range by \$0.30 due to tax rate change

	Prior Outlook	Updated Outlook
Adjusted EBITDA		
- Specialty Ingredients	\$560 - \$590 million	No change
- Composites	\$85 - \$95 million	No change
- Intermediates & Solvents	\$40 - \$50 million	No change
- Unallocated and Other	(\$35 - \$45 million)	No change
Key Operating Metrics		
- Free cash flow ¹	> \$220 million	No change
- Adj. earnings per share (EPS)	\$3.20 - \$3.40	\$2.90 - \$3.10
		(Update due to tax rate change)
Corporate Items		
- Depreciation & amortization	~\$290 million	No change
- Interest expense	\$125 - \$135 million	No change
- Effective tax rate	8 - 13%	16 - 20%
- Capital expenditures	\$195 - \$205 million	No change
- Diluted share count	~64 million	No change

1. Definition of free cash flow: operating cash flow less capital expenditures and other items Ashland has deemed non-operational (if applicable).

Ashland Global Holdings Inc.

Second-Quarter Fiscal 2018 Outlook

Highlights

- Expect Q2 adjusted EPS in the range of \$0.80 - \$0.90 vs. \$0.70 prior year
- Outlook based on effective tax rate of 18% vs. 1% prior year

Key Drivers

- Strong YOY organic sales and EBITDA growth in Specialty Ingredients, Composites and Intermediates & Solvents (I&S)
- Continued contribution from recent acquisitions consistent with expectations
- Planned I&S plant turnaround results in ~\$5 million of incremental YOY cost for the segment

Appendix A: Key Items and Balance Sheet

Fiscal First Quarter – Continuing Operations

Key Items Affecting Income

(\$ in millions, except EPS) Preliminary	Operating Income				Total		
	Specialty Ingredients	Composites	I&S	Unallocated and Other	Pre-tax	After-tax	Earnings per Share
2018							
Separation & restructuring costs	\$ (3)			\$ (11)	\$ (14)	\$ (10)	\$ (0.17)
Environmental reserve adjustment				(11)	(11)	(8)	(0.13)
Tax discrete items					-	(16)	(0.24)
Total	\$ (3)			\$ (22)	\$ (25)	\$ (34)	\$ (0.54)
2017							
Separation costs				\$ (22)	\$ (22)	\$ (15)	\$ (0.25)
Legal reserve				(5)	(5)	(3)	(0.04)
Debt refinancing costs					(92)	(56)	(0.90)
Gain on post-employ. benefits					2	1	0.02
Tax discrete items					-	(1)	(0.02)
Total				\$ (27)	\$ (117)	\$ (74)	\$ (1.19)

Liquidity and Net Debt

(\$ in millions)

Liquidity	
Cash	\$ 601
Revolver and A/R facility availability	498
Liquidity	\$ 1,099

Debt	Expiration	Interest			
		Rate	Moody's	S&P	
4.750% senior notes, par \$1,086	08/2022	4.750%	Ba3	BB-	\$ 1,082
Term Loan B ¹	05/2024	L + 200	Ba1	BB+	597
6.875% senior notes, par \$375	05/2043	6.875%	Ba3	BB-	376
Term Loan A-1 ²	05/2020	L + 175	Ba1	BB+	250
Term Loan A-2 ³	05/2022	L + 175	Ba1	BB+	250
6.5% debentures, par \$100	06/2029	6.500%	B2	BB	51
Revolver drawn ⁴	05/2022	L + 175	Ba1	BB+	285
A/R facility drawn ⁵	03/2018	CP + 60			64
Other debt					(16)
Total debt			Ba2 / Stable	BB / Stable	\$ 2,939
Cash					\$ 601
Net debt (cash)					\$ 2,338

¹ The Term Loan B has an amortizing principal, with complete repayment in 2024.

² The Term Loan A-1 has a complete repayment in 2020.

³ The Term Loan A-2 has an amortizing principal, with complete repayment in 2022.

⁴ Ashland's \$800 million revolving facility, including \$48 million used for letters of credit; December 31 capacity of \$467 million.

⁵ Ashland has an AR securitization facility with maximum borrowing capacity of \$95 million; December 31 capacity of \$31 million.



Appendix B: Business Profiles


12 Months Ended December 31, 2017




Corporate Profile

Sales¹ - \$3.4 Billion

By business unit



By geography




¹ For 12 months ended December 31, 2017.

² Ashland includes only U.S. and Canada in its North America designation.

Corporate Profile

Adjusted EBITDA¹ - \$597 Million



NYSE Ticker Symbol: ASH

Total Employees: ~6,500

Outside North America ~50%


Number of Countries in Which Ashland Has Sales: More than 100

¹ For 12 months ended December 31, 2017. See Appendix C for reconciliation to amounts reported under GAAP.



Specialty Ingredients

A global leader of cellulose ethers, vinyl pyrrolidones and biofunctionals



For 12 Months Ended December 31, 2017

Sales: \$2.3 billion

Adjusted EBITDA: \$504 million¹

Adjusted EBITDA Margin: 22.1%¹

¹ See Appendix C for reconciliation to amounts reported under GAAP.

² Within the Sales by Market chart above, Industrial Specialties are presented in green and Consumer Specialties are presented in blue.


³ Includes Pharmachem's sales for the period May 17, 2017 through December 31, 2017, the period for which Pharmachem was owned.




Composites

A global leader in unsaturated polyester resins, vinyl ester resins and gel coats


Sales
by Market



Sales
by Product



Sales
by Geography



For 12 Months Ended December 31, 2017

Sales: \$832 million

Adjusted EBITDA: \$91 million¹

Adjusted EBITDA Margin: 10.9%¹


¹ See Appendix C for reconciliation to amounts reported under GAAP.

² UPR stands for unsaturated polyester resins and VER stands for vinyl ester resins.


Intermediates and Solvents

A global leader in butanediol and related derivatives


Sales
by Application



Sales
by Product



Sales
by Geography



For 12 Months Ended December 31, 2017

Sales: \$283 million

Adjusted EBITDA: \$41 million¹

Adjusted EBITDA Margin: 14.5%¹

Appendix C: Non-GAAP Reconciliation¹

- 1 Although Ashland provides forward looking guidance for adjusted EBITDA in this presentation, Ashland is not reaffirming or providing forward-looking guidance for U.S. GAAP reported financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items without unreasonable effort.



Ashland Global Holdings Inc. and Consolidated Subsidiaries

Reconciliation of Non-GAAP Data

for 12 Months Ended December 31, 2017


(\$ millions, except percentages)

Sales ¹	Q1 18	Q4 17	Q3 17	Q2 17	Total	
Specialty Ingredients	550	598	591	544	2,283	
Composites	218	219	209	186	832	
Intermediates and Solvents	74	63	70	76	283	
Total	842	880	870	806	3,398	

Adjusted EBITDA ¹	Q1 18	Q4 17	Q3 17	Q2 17	Total	Adjusted EBITDA Margin
Specialty Ingredients	105	141	131	127	504	22.1%
Composites	23	23	27	18	91	10.9%
Intermediates and Solvents	16	10	10	5	41	14.5%
Unallocated	(8)	(13)	(7)	(11)	(39)	
Total	136	161	161	139	597	

¹ Quarterly totals may not sum to actual results due to quarterly rounding conventions. Calculation of adjusted EBITDA for each quarter has been reconciled within certain financial filings with the SEC and posted on Ashland's website for each reportable segment.





AshlandTM
always solving